These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 26226403)

  • 61. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
    Natesan S; Reckless GE; Barlow KB; Nobrega JN; Kapur S
    Schizophr Res; 2008 Oct; 105(1-3):224-35. PubMed ID: 18710798
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Drug brain distribution following intranasal administration of Huperzine A in situ gel in rats.
    Zhao Y; Yue P; Tao T; Chen QH
    Acta Pharmacol Sin; 2007 Feb; 28(2):273-8. PubMed ID: 17241531
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Behavioral patterns related to dopamine neurotransmission: effect of acute and chronic antipsychotic drugs.
    Ungerstedt U; Ljungberg T
    Adv Biochem Psychopharmacol; 1977; 16():193-9. PubMed ID: 18882
    [No Abstract]   [Full Text] [Related]  

  • 64. Treatment with haloperidol and diazepam alters GABA(A) receptor density in the rat brain.
    McLeod MC; Sundram S; Dean B
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):560-7. PubMed ID: 18045761
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nano-ropinirole for the management of Parkinsonism: blood-brain pharmacokinetics and carrier localization.
    Mustafa G; Ahuja A; Al Rohaimi AH; Muslim S; Hassan AA; Baboota S; Ali J
    Expert Rev Neurother; 2015 Jun; 15(6):695-710. PubMed ID: 25955028
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of chronic treatment with haloperidol on [3H]PK 11195 binding in the rat brain and peripheral tissues.
    Kurumaji A; Kaneko K; Toru M
    Neuropharmacology; 1996; 35(8):1075-9. PubMed ID: 9121610
    [TBL] [Abstract][Full Text] [Related]  

  • 67. UEA I-bearing nanoparticles for brain delivery following intranasal administration.
    Gao X; Chen J; Tao W; Zhu J; Zhang Q; Chen H; Jiang X
    Int J Pharm; 2007 Aug; 340(1-2):207-15. PubMed ID: 17499948
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of acute or chronic administration of risperidone on motor and sexual behavior of male rats.
    Drago F; Contarino A; Marino R; Anzallo C; Valerio C; Rampello L; Raffaele R; Scapagnini U
    Pharmacol Res; 1997 Jan; 35(1):17-25. PubMed ID: 9149311
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin.
    Huang X; Wu Z; Gao W; Chen Q; Yu B
    Drug Dev Ind Pharm; 2011 Apr; 37(4):419-27. PubMed ID: 20942611
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Poly(ethylene oxide/propylene oxide) copolymer thermo-reversible gelling system for the enhancement of intranasal zidovudine delivery to the brain.
    Ved PM; Kim K
    Int J Pharm; 2011 Jun; 411(1-2):1-9. PubMed ID: 21356294
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Emulsion formulations of testosterone for nasal administration.
    Ko KT; Needham TE; Zia H
    J Microencapsul; 1998; 15(2):197-205. PubMed ID: 9532525
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine.
    Qian S; Wong YC; Zuo Z
    Int J Pharm; 2014 Jul; 468(1-2):272-82. PubMed ID: 24709220
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Paliperidone microemulsion for nose-to-brain targeted drug delivery system: pharmacodynamic and pharmacokinetic evaluation.
    Patel MR; Patel RB; Bhatt KK; Patel BG; Gaikwad RV
    Drug Deliv; 2016; 23(1):346-54. PubMed ID: 24865295
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.
    Baltzley S; Mohammad A; Malkawi AH; Al-Ghananeem AM
    AAPS PharmSciTech; 2014 Dec; 15(6):1598-602. PubMed ID: 25142821
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Physicochemical and physiological considerations for efficient nose-to-brain targeting.
    Bahadur S; Pathak K
    Expert Opin Drug Deliv; 2012 Jan; 9(1):19-31. PubMed ID: 22171740
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue.
    Horvát S; Fehér A; Wolburg H; Sipos P; Veszelka S; Tóth A; Kis L; Kurunczi A; Balogh G; Kürti L; Eros I; Szabó-Révész P; Deli MA
    Eur J Pharm Biopharm; 2009 May; 72(1):252-9. PubMed ID: 19007885
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Optimization and in vivo toxicity evaluation of G4.5 PAMAM dendrimer-risperidone complexes.
    Prieto MJ; del Rio Zabala NE; Marotta CH; Carreño Gutierrez H; Arévalo Arévalo R; Chiaramoni NS; del Valle Alonso S
    PLoS One; 2014; 9(2):e90393. PubMed ID: 24587349
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Parenteral nanoemulsions of risperidone for enhanced brain delivery in acute psychosis: Physicochemical and in vivo performances.
    Đorđević SM; Santrač A; Cekić ND; Marković BD; Divović B; Ilić TM; Savić MM; Savić SD
    Int J Pharm; 2017 Nov; 533(2):421-430. PubMed ID: 28552767
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dendrimers: a class of polymers in the nanotechnology for the delivery of active pharmaceuticals.
    Samad A; Alam MI; Saxena K
    Curr Pharm Des; 2009; 15(25):2958-69. PubMed ID: 19754372
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Brain Targeting by Intranasal Drug Delivery: Effect of Different Formulations of the Biflavone "Cupressuflavone" from
    Khafagy ES; Soliman GA; Shahba AA; Aldawsari MF; Alharthy KM; Abdel-Kader MS; Zaatout HH
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36771021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.